Ildiko Csiki

1.0k total citations · 1 hit paper
25 papers, 663 citations indexed

About

Ildiko Csiki is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Ildiko Csiki has authored 25 papers receiving a total of 663 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Molecular Biology and 9 papers in Immunology. Recurrent topics in Ildiko Csiki's work include Immunotherapy and Immune Responses (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Inflammatory mediators and NSAID effects (5 papers). Ildiko Csiki is often cited by papers focused on Immunotherapy and Immune Responses (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Inflammatory mediators and NSAID effects (5 papers). Ildiko Csiki collaborates with scholars based in United States and New Zealand. Ildiko Csiki's co-authors include Jason D. Morrow, David P. Carbone, David H. Johnson, John A. Oates, Loretta M. Byrne, David H. Johnson, Laine J. Murphey, Stephanie Sanchez, Yu Shyr and Jerry J. Jaboin and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ildiko Csiki

23 papers receiving 651 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial

2024 111 citations Mark Yarchoan, Edward Gane et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ildiko Csiki United States	9	229	217	203	130	121	25	663
Roberta Sarmiento Italy	11	190 0.8×	167 0.8×	235 1.2×	79 0.6×	135 1.1×	19	591
Regina Courtney United States	10	195 0.9×	109 0.5×	97 0.5×	101 0.8×	89 0.7×	17	458
Pamela L. Rice United States	12	375 1.6×	99 0.5×	176 0.9×	105 0.8×	110 0.9×	15	648
Labile Togba Soumaoro Japan	6	140 0.6×	170 0.8×	134 0.7×	29 0.2×	101 0.8×	7	405
Masayuki Futagami Japan	16	405 1.8×	49 0.2×	226 1.1×	67 0.5×	156 1.3×	62	957
Reiko Dehari Japan	7	273 1.2×	91 0.4×	250 1.2×	79 0.6×	146 1.2×	15	852
A. Kominea Greece	11	267 1.2×	67 0.3×	212 1.0×	50 0.4×	122 1.0×	12	640
Thomas Barkley United States	9	104 0.5×	110 0.5×	210 1.0×	18 0.1×	166 1.4×	10	486
Karen Zempolich United States	11	219 1.0×	152 0.7×	196 1.0×	16 0.1×	89 0.7×	18	635
Anna Apicella Italy	10	125 0.5×	84 0.4×	115 0.6×	37 0.3×	77 0.6×	16	357

Countries citing papers authored by Ildiko Csiki

Since Specialization

Citations

This map shows the geographic impact of Ildiko Csiki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ildiko Csiki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ildiko Csiki more than expected).

Fields of papers citing papers by Ildiko Csiki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ildiko Csiki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ildiko Csiki. The network helps show where Ildiko Csiki may publish in the future.

Co-authorship network of co-authors of Ildiko Csiki

This figure shows the co-authorship network connecting the top 25 collaborators of Ildiko Csiki. A scholar is included among the top collaborators of Ildiko Csiki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ildiko Csiki. Ildiko Csiki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yarchoan, Mark, Edward Gane, Thomas U. Marron, et al.. (2024). Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial. Nature Medicine. 30(4). 1044–1053. 111 indexed citations breakdown →

Segar, Jennifer, Jordan Berlin, Ralph V. Boccia, et al.. (2024). 665P Safety, PK, immune activation, and clinical outcomes with RBS2418 treatment, an oral ENPP1 inhibitor, alone or in combination with pembrolizumab in advanced solid tumors. Annals of Oncology. 35. S523–S523. 1 indexed citations

Marron, Thomas U., Charles Chen, Zev A. Wainberg, et al.. (2023). 1025MO Preliminary safety, pharmacokinetics and immunomodulatory activity of RBS2418, an oral ENPP1 inhibitor, alone and in combination with pembrolizumab in patients with solid tumors. Annals of Oncology. 34. S623–S624. 5 indexed citations

Yarchoan, Mark, Edward Gane, Alfredo Perales‐Puchalt, et al.. (2022). 691 Immune pressure in an advanced hepatocellular cancer patient following treatment with personalized neoantigen DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab). Regular and Young Investigator Award Abstracts. A722–A722.

Gane, Edward, Mark Yarchoan, Thomas U. Marron, et al.. (2022). 693 Personalized DNA neoantigen vaccine (GNOS-PV02) in combination with plasmid IL-12 and pembrolizumab as second-line (2L) treatment for advanced hepatocellular carcinoma (HCC). Regular and Young Investigator Award Abstracts. A724–A724. 1 indexed citations

Perales‐Puchalt, Alfredo, Gábor Bartha, Josette Northcott, et al.. (2022). 692 Circulating tumor DNA analysis of advanced hepatocellular cancer (HCC) patients treated with neoantigen targeted personalized cancer DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab). Regular and Young Investigator Award Abstracts. A723–A723. 5 indexed citations

Yarchoan, Mark, Edward Gane, Thomas U. Marron, et al.. (2021). 453 Personalized DNA neoantigen vaccine (GNOS-PV02) in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma. SHILAP Revista de lepidopterología. A481–A481. 8 indexed citations

Shore, Neal D., Elisabeth I. Heath, Luke T. Nordquist, et al.. (2018). Evaluation of an immunotherapeutic DNA-vaccine in biochemically relapsed prostate cancer.. Journal of Clinical Oncology. 36(15_suppl). 5078–5078.

Shore, Neal D., Elisabeth I. Heath, Luke T. Nordquist, et al.. (2017). Safety and immunogenicity of a DNA-vaccine immunotherapy in men with biochemically (PSA) relapsed prostate cancer. Annals of Oncology. 28. v272–v272. 1 indexed citations

10.

Shore, Neal D., Elisabeth I. Heath, Luke T. Nordquist, et al.. (2017). A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer.. Journal of Clinical Oncology. 35(15_suppl). e14634–e14634. 1 indexed citations

11.

Aggarwal, Charu, Roger B. Cohen, Matthew P. Morrow, et al.. (2017). Immunogenicity results using human papillomavirus (HPV) specific DNA vaccine, INO-3112 (HPV16/HPV18 plasmids + IL-12) in HPV+ head and neck squamous cell carcinoma (HNSCCa).. Journal of Clinical Oncology. 35(15_suppl). 6073–6073. 6 indexed citations

12.

Savani, Malvi, Yan Guo, David P. Carbone, & Ildiko Csiki. (2012). Sonic hedgehog pathway expression in non-small cell lung cancer. Therapeutic Advances in Medical Oncology. 4(5). 225–233. 14 indexed citations

13.

Novitskiy, Sergey V., Ildiko Csiki, Yuhui Huang, et al.. (2010). Anti-Vascular Endothelial Growth Factor Treatment in Combination with Chemotherapy Delays Hematopoietic Recovery Due to Decreased Proliferation of Bone Marrow Hematopoietic Progenitor Cells. Journal of Thoracic Oncology. 5(9). 1410–1415. 16 indexed citations

14.

Spratt, Daniel E., et al.. (2010). Impact of FDG PET/CT on Delineation of the Gross Tumor Volume for Radiation Planning in Non–Small-Cell Lung Cancer. Clinical Nuclear Medicine. 35(4). 237–243. 19 indexed citations

15.

Csiki, Ildiko, David H. Johnson, David P. Carbone, et al.. (2007). A Phase II Study of Celecoxib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy for Patients With Inoperable Stage IIIA/B Non-Small Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 69(3). S524–S524. 1 indexed citations

16.

Csiki, Ildiko, Kiyoshi Yanagisawa, Nobuhiro Haruki, et al.. (2006). Thioredoxin-1 Modulates Transcription of Cyclooxygenase-2 via Hypoxia-Inducible Factor-1α in Non–Small Cell Lung Cancer. Cancer Research. 66(1). 143–150. 79 indexed citations

17.

Csiki, Ildiko, Jason D. Morrow, Alan Sandler, et al.. (2005). Targeting Cyclooxygenase-2 in Recurrent Non–Small Cell Lung Cancer: A Phase II Trial of Celecoxib and Docetaxel. Clinical Cancer Research. 11(18). 6634–6640. 91 indexed citations

18.

Murphey, Laine J., Stephanie Sanchez, Loretta M. Byrne, et al.. (2004). Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer. Analytical Biochemistry. 334(2). 266–275. 141 indexed citations

19.

Csiki, Ildiko, Yu Shyr, Alan Sandler, et al.. (2004). Urine PGE-M as a marker of intratumoral cyclooxygenase-2 activity in non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 22(14_suppl). 9527–9527. 1 indexed citations

20.

Freund, Joel S., et al.. (2002). Case-Mixing Effects on Anagram Solution. The Journal of General Psychology. 129(2). 117–126. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact